"NodThera's NLRP3 Inhibitors Show Promise for Weight Loss"

NodThera is advancing its NLRP3 inhibitors into clinical trials after preclinical data demonstrated their potential to reverse obesity and inflammation in mice, with its lead candidate, NT-0796, resulting in a 19% weight loss in mice over 28 days, comparable to the weight loss seen with No­vo Nordisk’s We­govy.